e-ISSN: Pending
Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens

Temporal evolution of breast cancer brain metastases treatments and outcomes

Michele Bottosso; Gaia Griguolo; Severine Guiu; Maria Cristina Guarascio; Caroline Bailleux; Federica Miglietta; Anna Chiara Cattelan; Christian Zurlo · 2025 · npj Breast Cancer

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Abstract Brain metastases (BMs) are a common complication of advanced breast cancer (BC), and their management has significantly evolved. We evaluated the clinical impact of these changes dividing patients diagnosed with BCBMs at three Institutions according to year of BMs diagnosis: 2000-2007 (group A), 2008-2014 (group B) and 2015-2022 (group C). Stereotactic radiotherapy increased (p < 0.001), and WBRT decreased (p = 0.010) over time. Among HER2+ BC patients, more received anti-HER2 therapy after BM diagnosis in recent years (p < 0.011). Overall survival (OS) did not improve in the entire c

Abstract by Michele Bottosso; Gaia Griguolo; Severine Guiu; Maria Cristina Guarascio; Caroline Bailleux; Federica Miglietta; Anna Chiara Cattelan; Christian Zurlo, npj Breast Cancer (2025) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1038/s41523-025-00735-w